Willis Towers Watson PLC (WTY.HA)
| Previous Close | 246.00 |
| Open | 244.00 |
| Bid | 240.00 x N/A |
| Ask | 242.00 x N/A |
| Day's Range | 244.00 - 244.00 |
| 52 Week Range | 179.00 - 256.00 |
| Volume | |
| Avg. Volume | 0 |
| Market Cap | N/A |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
WTW announces leadership change in Australia and New Zealand to foster continued growth
James Baum is appointed as Head of Australia and New Zealand and Head of Corporate Risk & Broking Australia and New ZealandSYDNEY, July 01, 2024 (GLOBE NEWSWIRE) -- WTW (NASDAQ: WTW), a leading global advisory, broking, and solutions company, today announced the appointment of James Baum as WTW Head of Australia and New Zealand, and Head of Corporate Risk & Broking (CRB) Australia and New Zealand, effective 15 July. Simon Weaver will continue to serve as WTW Head of Asia Pacific and Head of CRB
- GlobeNewswire
WTW publishes second annual sustainability report
NEW YORK, June 28, 2024 (GLOBE NEWSWIRE) -- WTW, a leading global advisory, broking, and solutions company has published its second annual sustainability report, Taking Action to Create Sustainable Value, outlining the company’s sustainability programs, commitments and accomplishments. The report provides information on the broad range of WTW activities and achievements across the environmental, people and community, and governance efforts that impact the company’s internal business operations.
- GlobeNewswire
Cost of new drug development is key concern for life science as focus shifts to repurposing
LONDON, June 27, 2024 (GLOBE NEWSWIRE) -- 63% of life science companies believe the high cost of new drug development is among the emerging themes that will have the greatest negative impact on the sector in the next 3-5 years, according to Global life science risk report 2024 published today by WTW (NASDAQ: WTW), a leading global advisory, broking, and solutions company. This is leading to an increased focus on finding novel use cases for existing drugs, named by 66% as having a positive impact
